Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses
Open Access
- 21 August 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Health and Quality of Life Outcomes
- Vol. 6 (1), 65
- https://doi.org/10.1186/1477-7525-6-65
Abstract
Background Pulmonary Hypertension is a severe and incurable disease with poor prognosis. A suite of new disease-specific measures – the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) – was recently developed for use in this condition. The purpose of this study was to develop and validate a preference based measure from the CAMPHOR that could be used in cost-utility analyses. Methods Items were selected that covered major issues covered by the CAMPHOR QoL scale (activities, travelling, dependence and communication). These were used to create 36 health states that were valued by 249 people representative of the UK adult population, using the time trade-off (TTO) technique. Data from the TTO interviews were analysed using both aggregate and individual level modelling. Finally, the original CAMPHOR validation data were used to validate the new preference based model. Results The predicted health state values ranged from 0.962 to 0.136. The mean level model selected for analyzing the data had good explanatory power (0.936), did not systematically over- or underestimate the observed mean health state values and showed no evidence of auto correlation in the prediction errors. The value of less than 1 reflects a background level of ill health in state 1111, as judged by the respondents. Scores derived from the new measure had excellent test-retest reliability (0.85) and construct validity. The CAMPHOR utility score appears better able to distinguish between WHO functional classes (II and III) than the EQ-5D and SF-6D. Conclusion The tariff derived in this study can be used to classify an individual into a health state based on their responses to the CAMPHOR. The results of this study widen the evidence base for conducting economic evaluations of interventions designed to improve QoL for patients with PH.Keywords
This publication has 18 references indexed in Scilit:
- The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control statusQuality of Life Research, 2008
- Estimation of a Preference-Based Index from a Condition-Specific Measure: The King's Health QuestionnaireMedical Decision Making, 2007
- Quality of Life in Pulmonary Arterial Hypertension: Improvement and Maintenance With BosentanThe Journal of Heart and Lung Transplantation, 2007
- Responsiveness of disease-specific and generic utility instruments in prostate cancer patientsQuality of Life Research, 2006
- The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary HypertensionQuality of Life Research, 2006
- A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programmeHealth Technology Assessment, 2004
- Prostanoids for Pulmonary Arterial HypertensionAmerican Journal of Respiratory Medicine, 2003
- Decision validity should determine whether a generic or condition‐specific HRQOL measure is used in health care decisionsHealth Economics, 2002
- Integrating Patient Preferences Into Health Outcomes AssessmentChest, 1998
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997